Humanized hiPSC Platforms for I/R Injury: Advancing Toward Precision Cardioprotection
Cardiovascular Therapeutics · 2026
DOI: 10.1155/cdr/2729114 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Mengyan Mi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ningbo University, Ningbo, Zhejiang, China, nbu.edu.cn. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Myocytes, Cardiac, Myocardial Reperfusion Injury, Precision Medicine. Die Arbeit nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Myocardial ischemia–reperfusion (I/R) injury remains a major contributor to infarct expansion, adverse remodeling, and heart failure despite timely coronary revascularization. The repeated failure of cardioprotective interventions that were effective in animal models has exposed a persistent translational gap. Human induced pluripotent stem cell–derived cardiomyocytes (hiPSC‐CMs) and engineered cardiac platforms preserve donor‐specific human genetic backgrounds, provide scalable cell sources, and offer experimentally tractable systems for studying selected mechanisms of I/R injury. Recent advances in electrical, mechanical, metabolic, and endocrine maturation, together with engineered heart tissues (EHTs), cardiac organoids, and perfused heart‐on‐a‐chip platforms, have improved the ability to model cardiomyocyte stress, calcium overload, mitochondrial dysfunction, oxidative injury, and multicellular crosstalk. Single‐cell and spatial omics, CRISPR‐based perturbation, and artificial intelligence (AI)–assisted high‐content phenotyping further enable state‐resolved and mechanistically testable analyses of vulnerable cardiac cell populations. In this narrative review, we synthesize recent progress in hiPSC‐based myocardial I/R modeling, critically evaluate the strengths and limitations of current platforms, and discuss their use in mechanism‐guided drug screening, cardiotoxicity assessment, and patient‐specific preclinical modeling. We emphasize that these systems are not yet substitutes for clinical validation or whole‐organ physiology. Their current value lies in providing controllable, human‐relevant preclinical models that can prioritize mechanisms, identify candidate interventions, and support better‐designed translational cardioprotection studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ningbo University, Ningbo, Zhejiang, China, nbu.edu.cn.
- Department of Cardiology, Ningbo Medical Centre Lihuili Hospital, Ningbo, Zhejiang, China.
- Science and Technology R&D Department, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China, nbws.gov.cn.
ORCID-Profile: Mengyan Mi, Tzu-Yu Chen, Honghua Ye
Zitieren
APA
Mi, M., Chen, T. Y., & Ye, H. (2026). Humanized hiPSC Platforms for I/R Injury: Advancing Toward Precision Cardioprotection. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/2729114
Vancouver
Mi M, Chen TY, Ye H. Humanized hiPSC Platforms for I/R Injury: Advancing Toward Precision Cardioprotection. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/2729114
BibTeX
@article{Mi2026,
author = {Mi, Mengyan and Chen, Tzu-Yu and Ye, Honghua},
title = {Humanized hiPSC Platforms for I/R Injury: Advancing Toward Precision Cardioprotection},
journal = {Cardiovascular Therapeutics},
year = {2026},
doi = {10.1155/cdr/2729114}
}
EUVIMED